Advertisement
U.S. markets close in 3 hours 21 minutes
  • S&P 500

    4,593.72
    +25.92 (+0.57%)
     
  • Dow 30

    36,195.90
    +245.01 (+0.68%)
     
  • Nasdaq

    14,291.00
    +64.78 (+0.46%)
     
  • Russell 2000

    1,850.45
    +41.44 (+2.29%)
     
  • Crude Oil

    76.07
    +0.11 (+0.14%)
     
  • Gold

    2,080.70
    +23.50 (+1.14%)
     
  • Silver

    25.78
    +0.12 (+0.49%)
     
  • EUR/USD

    1.0884
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    4.2590
    -0.0930 (-2.14%)
     
  • GBP/USD

    1.2691
    +0.0064 (+0.51%)
     
  • USD/JPY

    146.9650
    -1.2000 (-0.81%)
     
  • Bitcoin USD

    38,756.73
    +1,032.62 (+2.74%)
     
  • CMC Crypto 200

    800.77
    +9.22 (+1.16%)
     
  • FTSE 100

    7,529.35
    +75.60 (+1.01%)
     
  • Nikkei 225

    33,431.51
    -55.38 (-0.17%)
     

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK Therapeutics
MiNK Therapeutics

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797’s distinct mechanism of action in solid tumors. A poster will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting on November 1-5, 2023.

Presentation Details

Title: Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer

Presenting Author: Marco Purbhoo, Ph.D., Head of Translational Research, MiNK Therapeutics

Abstract Number: 735

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ and our Twitter handle @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and Twitter.

Investor Contact
917-362-1370
investor@minktherapeutics.com

Media Contact
781-674-4428
communications@minktherapeutics.com



Advertisement